Quick Liquidity Indicator: MacroGenics Inc. (MGNX)

MGNX (MacroGenics, Inc.) - company brandmark

This daily price chart for MacroGenics, Inc. (MGNX) reflects the asset's dynamics, with a value of 2.89. MacroGenics, Inc. (MGNX) possesses pricing power driven by its DART platform for bispecific antibody development. Business growth relies on ADC drug test results, royalty payments from Margenza, and partnerships with industry behemoths. Additionally, the firm is competing scientifically against the largest pharma pipelines by developing high-precision oncology therapies.

MGNX: MacroGenics Inc Intermediate Coverage Ratio 07/04/2022 - 10/29/2026

MGNX (macrogenics.com): analytical breakdowns and indicator data

- market value and analyst target forecast:
Price Chart MacroGenics Corp|MGNX - Analyst Median Target
- company stock exchange capitalization indicators:
Market Valuation MacroGenics Corp|MGNX - Aggregate Business Value
- book capitalization indicators:
Accounting Value per Share MacroGenics|MGNX - Accounting Value of Company|Market Capitalization to Book Value Ratio macrogenics.com|MGNX - Cumulative Company Assets
- company total debt and liquidity indicators:
Total Debt to Capital MacroGenics, Inc.|MGNX - Long-Term Debt to Capital|Short-Term Debt to Equity MacroGenics|MGNX - Company Aggregate Debt|Debts to Book Capitalization MacroGenics Corp|MGNX - Company Long-Term Liabilities|Company Short-Term Debts MacroGenics|Quick Liquidity macrogenics.com
- earnings and valuation multiples information:
MGNX - Final Profit
Summary company analysis:MacroGenics Corp - MGNX
Flagship merchandise of MacroGenics

This ratio assesses the ability of MacroGenics, Inc. (MGNX) to settle short-term liabilities using its most liquid assets, excluding slow-moving inventories. An analysis of the quick ratio is critical for MacroGenics, Inc. (MGNX), as cash availability determines the pace of bringing targeted antibodies to market and the success of clinical trials, regardless of external macroeconomic factors.

Main competitors

Olema Pharma (OLMA) - Quick Liquidity|PBYI - Interim Coverage Ratio|Quick Liquidity Indicator GLSI|ZNTL (zentalis.com) - Intermediate Liquidity Ratio|Quick Liquidity Indicator PSTV (Plus Therapeutics, Inc.)|PCSA (processapharmaceuticals.com) - Intermediate Coverage Ratio|Quick Ratio EGRX (Eagle Pharmaceuticals, Inc.)